ArticleActa oncologica (Stockholm, Sweden)2025

Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study.

Xiaoyan Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.